Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead 
Welcome,         Profile    Billing    Logout  
 50 Diseases   11 Trials   11 Trials   833 News 


«123456789101112»
  • ||||||||||  Lexiscan / Astellas
    Clinical, Journal:  The prognostic value of ultra low-dose thallium myocardial perfusion protocol using CZT SPECT. (Pubmed Central) -  Jun 15, 2019   
    ...The stress test was performed by bicycle ergometry or regadenoson injection...In patients with ischaemia there were 21 (29.2%) subjects with cardiac events, and 23 (7.9%) in patients without ischaemia (HR 4.15, 95% CI 2.30-7.51, p < 0.0001). Ultra-low dose thallium perfusion imaging using CZT camera provides very good prognostic results in assessment of myocardial ischaemia.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) -  Jun 14, 2019   
    P=N/A,  N=90, Active, not recruiting, 
    Ultra-low dose thallium perfusion imaging using CZT camera provides very good prognostic results in assessment of myocardial ischaemia. Trial completion date: Jul 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jan 2020
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer (clinicaltrials.gov) -  May 30, 2019   
    P=N/A,  N=24, Recruiting, 
    Trial completion date: Jul 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jan 2020 Trial completion date: May 2020 --> Aug 2020 | Trial primary completion date: May 2019 --> Aug 2019
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date:  Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking (clinicaltrials.gov) -  May 16, 2019   
    P4,  N=300, Active, not recruiting, 
    Trial completion date: May 2020 --> Aug 2020 | Trial primary completion date: May 2019 --> Aug 2019 Trial completion date: Aug 2020 --> Aug 2021
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment open:  Allograft Dysfunction in Heart Transplant (clinicaltrials.gov) -  Apr 22, 2019   
    P4,  N=36, Recruiting, 
    Further clinical validation is warranted. Not yet recruiting --> Recruiting
  • ||||||||||  Lexiscan / Astellas
    Review, Journal:  Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. (Pubmed Central) -  Apr 16, 2019   
    ...Currently, short-acting, parenteral agonists, adenosine and Regadenoson, are the only AR agonists approved for human use...AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions and diabetes have been under development. Multiple clinical trials with two AAR agonists are ongoing.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment closed, Enrollment change, Trial completion date:  Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) -  Mar 11, 2019   
    P=N/A,  N=90, Active, not recruiting, 
    If confirmed in larger series, this approach may aid the interpretation of clinical stress perfusion exams. Enrolling by invitation --> Active, not recruiting | N=150 --> 90 | Trial completion date: Dec 2018 --> Jul 2019
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers (clinicaltrials.gov) -  Jan 30, 2019   
    P1,  N=70, Completed, 
    No abstract available Active, not recruiting --> Completed | N=145 --> 70 | Trial completion date: Jun 2020 --> Jan 2018 | Trial primary completion date: Jun 2020 --> Jan 2018
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Trial completion date, Trial primary completion date:  Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration (clinicaltrials.gov) -  Nov 20, 2018   
    P1,  N=6, Completed, 
    Active, not recruiting --> Completed | N=145 --> 70 | Trial completion date: Jun 2020 --> Jan 2018 | Trial primary completion date: Jun 2020 --> Jan 2018 Recruiting --> Completed | Trial completion date: Dec 2016 --> Feb 2018 | Trial primary completion date: Jul 2016 --> Feb 2016
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Enrollment change, Trial completion date:  Stress CT Perfusion in Patients With Chest Pain (clinicaltrials.gov) -  Oct 11, 2018   
    P=N/A,  N=150, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2016 --> Feb 2018 | Trial primary completion date: Jul 2016 --> Feb 2016 Recruiting --> Completed | N=300 --> 150 | Trial completion date: Jun 2019 --> Jun 2018
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  Review of cardiovascular imaging in the journal of nuclear cardiology in 2016: Part 2 of 2-myocardial perfusion imaging. (Pubmed Central) -  Aug 11, 2018   
    In the first article of this two-part series we focused on publications dealing with positron emission tomography, computed tomography, and magnetic resonance. This review will place emphasis on myocardial perfusion imaging using single-photon emission-computed tomography summarizing advances in the field including in diagnosis, prognosis, and appropriate use.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment open:  ArmCrank: Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome (clinicaltrials.gov) -  Jul 26, 2018   
    P=N/A,  N=300, Recruiting, 
    This review will place emphasis on myocardial perfusion imaging using single-photon emission-computed tomography summarizing advances in the field including in diagnosis, prognosis, and appropriate use. Not yet recruiting --> Recruiting
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment closed, Trial completion date, Trial primary completion date:  Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers (clinicaltrials.gov) -  Apr 26, 2018   
    P1,  N=145, Active, not recruiting, 
    Trial primary completion date: Mar 2018 --> Jun 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Clinical, Journal:  The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study. (Pubmed Central) -  Apr 13, 2018   
    While animal studies have demonstrated that regadenoson transiently increases the permeability of the BBB to dextran and temozolomide, we were unable to document changes in the penetration of contrast agents in humans with intact BBB using the FDA approved doses of regadenoson for cardiac evaluation. Further studies are needed exploring alternate regadenoson dosing, schedules, and studies in patients with brain tumors; as transiently disrupting the BBB to improve drug entry into the brain is critical to improving the care of patients with CNS malignancies.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Enrollment change, Trial completion date:  REDUCE: Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT (clinicaltrials.gov) -  Apr 13, 2018   
    P=N/A,  N=300, Completed, 
    Further studies are needed exploring alternate regadenoson dosing, schedules, and studies in patients with brain tumors; as transiently disrupting the BBB to improve drug entry into the brain is critical to improving the care of patients with CNS malignancies. Recruiting --> Completed | N=800 --> 300 | Trial completion date: Feb 2018 --> Oct 2017
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Phase classification:  ArmCrank: Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome (clinicaltrials.gov) -  Apr 4, 2018   
    P,  N=300, Not yet recruiting, 
    Recruiting --> Completed | N=800 --> 300 | Trial completion date: Feb 2018 --> Oct 2017 Phase classification: P=N/A --> P
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  RHINO: Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension (clinicaltrials.gov) -  Apr 3, 2018   
    P=N/A,  N=10, Terminated, 
    Phase classification: P=N/A --> P Trial completion date: Mar 2019 --> May 2017 | Trial primary completion date: Mar 2019 --> May 2017
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  A quick glance at selected topics in this issue. (Pubmed Central) -  Mar 28, 2018   
    Trial completion date: Mar 2019 --> May 2017 | Trial primary completion date: Mar 2019 --> May 2017 "A quick glance at selected topics in this issue" aims to highlight contents of the journal and provide a quick review to the readers.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla) (clinicaltrials.gov) -  Mar 23, 2018   
    P1,  N=333, Completed, 
    "A quick glance at selected topics in this issue" aims to highlight contents of the journal and provide a quick review to the readers. Recruiting --> Completed
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  A quick glance at selected topics in this issue. (Pubmed Central) -  Feb 19, 2018   
    Trial completion date: Feb 2018 --> Mar 2018 | Initiation date: Aug 2014 --> Sep 2014 | Trial primary completion date: Jan 2018 --> Jan 2018 "A quick glance at selected topics in this issue" aims to highlight few randomly selected articles and provide a quick review to the readers.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment open, Trial initiation date:  Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation (clinicaltrials.gov) -  Feb 8, 2018   
    P1,  N=21, Recruiting, 
    "A quick glance at selected topics in this issue" aims to highlight few randomly selected articles and provide a quick review to the readers. Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Nov 2017
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=100, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Nov 2017 Recruiting --> Completed
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial primary completion date:  HFpEF-PRoF: Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF (clinicaltrials.gov) -  Jan 17, 2018   
    P4,  N=60, Recruiting, 
    This review will focus on myocardial perfusion imaging summarizing advances in the field including in diagnosis, prognosis, and appropriate use. Trial primary completion date: Oct 2018 --> May 2020